Sr. Vice President and CFO of Medivation Inc. (MDVN, Financial) Clarence Patrick Machado sells 20,000 shares of MDVN on 11/11/2009 at an average price of $28.28 a share.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $938.2 million; its shares were traded at around $28.03 with and P/S ratio of 74.6.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices Medivation Inc. has a market cap of $938.2 million; its shares were traded at around $28.03 with and P/S ratio of 74.6.
Insiders' Positions with MDVN
- Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 09/10/2009 at the average price of 25.84, the price of the stock has increased by 8.48% since
- Sell:: President and CEO David Hung sold 25,000 shares of MDVN stock on 07/01/2009 at the average price of 22.62, the price of the stock has increased by 23.92% since
Insiders' Positions with MDVN
- Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 09/10/2009 at the average price of 25.86, the price of the stock has increased by 8.39% since
- Sell:: Sr. Vice President and CFO Clarence Patrick Machado sold 20,000 shares of MDVN stock on 07/01/2009 at the average price of 22.48, the price of the stock has increased by 24.69% since
Insiders' Positions with MDVN
- Sell:: Director Gregory Bailey sold 10,000 shares of MDVN stock on 09/14/2009 at the average price of 25.99, the price of the stock has increased by 7.85% since
- Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 09/10/2009 at the average price of 25.87, the price of the stock has increased by 8.35% since
- Sell:: Chief Commercial Officer Rohan Palekar sold 12,000 shares of MDVN stock on 09/10/2009 at the average price of 25.9, the price of the stock has increased by 8.22% since
- Sell:: Chief Medical Officer Lynn Seely sold 18,000 shares of MDVN stock on 07/01/2009 at the average price of 22.37, the price of the stock has increased by 25.3% since
- Sell:: Chief Commercial Officer Rohan Palekar sold 12,000 shares of MDVN stock on 06/30/2009 at the average price of 22.21, the price of the stock has increased by 26.2% since